Articles related to CLINICAL TRIALS

Both as oral monotherapy and in combination with cetuximab, adagrasib exhibited antitumor activity in patients who had received prior treatment and had metastatic colorectal cancer with mutant KRAS G12C. In the group receiving combination therapy, the median response time was greater than 6 months. Reversible negative outcomes were frequent in both groups.

Patients with previously untreated mantle cell lymphoma (MCL) have relied on autologous stem cell transplant (ASCT) for more than 20 years; the current standard of care entails high-dose cytarabine-containing chemoimmunotherapy, ASCT, and rituximab maintenance. A recent clinical trial’s findings, which revealed that FFS was superior to ASCT when ibrutinib medication was added, may change this.

A fully human IgG1 antibody that selectively binds to mutant CALR, INCA033989 demonstrated activity in cells from MPN patients and a mouse model of essential thrombocythemia. In the model, INCA033989 selectively decreased levels of mutant CALR-positive platelets, re-established normal megakaryopoiesis, and selectively targeted mutant CALR disease-initiating clones.

The researchers enrolled DLBCL patients with relapsed or refractory disease who had already received at least two lines of treatment in the phase 2 portion of a phase 1-2 investigation. They concluded that treatment with glofitamab was successful for DLBCL, with more than half of the patients experiencing a grade 3 or 4 adverse event.

Despite being mostly low-grade, cytokine release syndrome, skin-related events, and dysgeusia were frequent side effects of talquetamab therapy. Patients who had multiple myeloma that was relapsed or resistant after receiving substantial prior treatment had a significant response to talquetamab.

According to a news release from study lead author Colin Haile, a research associate professor of psychology at UH and the Texas Institute for Measurement, Evaluation and Statistics (TIMES) and a founding member of the UH Drug Discovery Institute, “Our vaccine is able to generate anti-fentanyl antibodies that bind to the consumed fentanyl and prevent it from entering the brain, allowing it to be eliminated out of the body via the kidneys.” The person won’t experience the euphoric benefits as a result, and they can “get back on the wagon” to sobriety.